Slide 1: Organic sales growth and solid cash flow
Organic sales growth and solid cash flow Getinge Q4 2025 Mattias Perjos, CEO Agneta Palmér, CFO
Slide 2: Key pillars for Getinge's profitable growth journey
Key pillars for Getinge’s profitable growth journey Development for strategic KPIs Increase share from recurring revenue Increase sales share from high margin products1 Less field actions per Bn SEK Net sales Capital goods Recurring revenue Rest of Portfolio High margin products -47% 1,9 1,2 1,0 61%
Slide 3: Key takeaways
Key takeaways Q4 2025 • Net sales grew by 1.2% organically and order intake increased by 2.3% organically • Margins in the quarter were heavily impacted by currency and tariffs – yet in line with 2024 for full year • Solid cashflow and financial position • Proposed dividend: 4.75 SEK/Share 37,000 53
Slide 4: Key activities and events
Key activities and events Q4 2025 Offering and Customers Sustainability and Quality • Backend loaded quarter – Great collaboration with customers • Premarket Approval (PMA) received for the iCast covered resulting in record high quarter in organic sales stent in two new versions • Integration of Sie
Slide 5: Organic growth in all Business Areas except Life Science
Organic growth in all Business Areas except Life Science Order Intake and Net Sales Bridge Q4 2024 – Q4 2025 Order Intake Net Sales Organic Organic change +3.1% -10.9% +6.2% +2.3% change +2.3% -3.4% +1.5% +1.2% -7.7% -8.0% -446 -164 -384 -275 -224 -110 SEK M SEK M 11,071 10,186 9,273 8,555 Q4 2024 A
Slide 6: Margins held up well despite headwinds from currency and tariffs
Margins held up well despite headwinds from currency and tariffs Adjusted Gross Profit and EBITA Bridge Q4 2024 – Q4 2025 Adjusted Gross Profit Adjusted EBITA Adj GM,% Margin development Q4 2025 58.0 35.2 43.0 49.5 -0.5 pp Adj GP (Q4 2024) (58.3) (41.3) (43.5) (50.6) -0.2 pp Adj OPEX +0.3 pp D&A -1.
Slide 7: Getinge continues to have a solid financial position
Getinge continues to have a solid financial position Strong FCF in quarter and good safety margin on leverage FCF positively impacted by improved operating profit… … and leverage continues to be well below 2.5x 1.6 1.7 1.6 1.4 1.5 1.7 1.7 1.2 1.6 1.4 1.6 1.5 0.8 0.5 (1.2x excl. pension liabilities)
Slide 8: We make a life saving difference
We make a life saving difference Getinge’s impact in a few selected figures More than every1 Every Every 4th 39% 95% Operating Table globally is increase in correctly of Getinge’s Life Science from Getinge and these planned surgeries by products are produced are used in over utilizing Torin, Getinge
Slide 9: 2025 – a year of consistent performance despite geopolitical friction
2025 – a year of consistent performance despite geopolitical friction The main themes of the year Geopolitical friction Progress in quality Several product Strong underlying and FX headwind remediation launches performance Getinge │ Presentation │ Q4 Report 2025 January 27, 2026
Slide 10: Tariffs and FX at peak level in Q4 diluting underlying margin by -2.5 pp
Tariffs and FX at peak level in Q4 diluting underlying margin by -2.5 pp Impact on margin from tariffs and FX Impact on adj EBITA in Q4 2025 Illustrative view on adj EBITA margin excl tariffs and FX in Q4 2024 vs Q4 2025 -464* 19.4 20.3 19.2 17.8 MSEK Q4 2024 Q4 2025 Reported adj EBITA margin Excl t
Slide 11: Progress in regulatory uplift plan with major milestones coming up in 2026
Progress in regulatory uplift plan with major milestones coming up in 2026 Regulatory product uplift plan in IABP and ECMO No sales restrictions √ H2 2025 CardioSave CE-markets when field actions are CE-mark reinstated done (Intra-Aortic Sell to existing Balloon Pump) USA customers, no □ Q2 2026 pro
Slide 12: Steady traction towards the financial target in 2028
Steady traction towards the financial target in 2028 Main profitability drivers Capital Market Update in May 2024 Adj. EBITA Margin bridge 2023-2028 Main drivers for improved profitability 2026-2028 • Key strategic product launches and regulatory approvals in 2026-2027 ~16-19% Growth • US pharma inv
Slide 13: 2026 – Setting up for acceleration in 2027-2028
2026 – Setting up for acceleration in 2027-2028 Expected main three themes of the year Geopolitical friction Hitting critical milestones Solid underlying and FX headwind in quality remediation performance Getinge │ Presentation │ Q4 Report 2025 January 27, 2026
Slide 14: Net sales for 2026 expected to increase by 3-5% organically
Outlook 2026 Net sales for 2026 expected to increase by 3-5% organically* * Adjusted for the phase out of Surgical Perfusion, which is expected to have net sales in 2026 declining from about 250 MSEK to 50 MSEK Getinge │ Presentation │ Q4 Report 2025 January 27, 2026
Slide 15: Summary
Summary Getinge │ Presentation │ Q4 Report 2025 January 27, 2026
Slide 16: Key takeaways
Key takeaways Summary Q4 2025 • Organic growth and record high sales • Margins heavily impacted by currency and tariffs – yet in line with 2024 for full year • The financial position remains solid • Outlook for 2026: organic net sales growth of 3-5%, adjusted for the phase out of Surgical Perfusion
Slide 17: Q&A
Q&A Getinge │ Presentation │ Q4 Report 2025 January 27, 2026
Slide 18: Thank you
Thank you Getinge │ Presentation │ Q4 Report 2025 January 27, 2026
Slide 19: Forward looking information
Forward looking information This document contains forward-looking information based on the current expectations of the Getinge’s management. Although management deems that the expectations presented by such forward-looking information are reasonable, no guarantee can be given that these expectation
Slide 20: GETINGE
al Se A GETINGE PASSION FOR LIFE